Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Mesothelioma × Vorinostat × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Multiple Myeloma 3 Neoplasms, Plasma Cell 2 Mycosis Fungoides 2 Lymphoma, T-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Pemetrexed 2 Cisplatin 2 talazoparib 1 milademetan 1 atezolizumab 1 Vorinostat 1 Talc 1 Surveys and Questionnaires 1 Cryosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353482 2012-03-22

MESO-02

University College, London

Phase 1/2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡